

RECEIVED

2007 MAY 17 A 9:12

OFFICE OF INTERNATIONAL
CORPORATE FINANCE

Office of International Corporate Finance
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Mail Stop 3628
Washington, D.C. 20549



07023608

Reykjavik, May 10 2007
File no. 90-07-0158

Re: Actavis Group hf. (File No. 82-34959)
Submission Pursuant to Rule 12g3-2(b)(iii)

SUPPL

Ladies and Gentlemen:

By letter dated February 13, 2006, a submission to the Securities and Exchange Commission (the "SEC") was made on behalf of Actavis Group hf. (the "Company") in order to establish the Company's exemption from the registration requirements of Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 12g3-2(b) promulgated under the Exchange Act. We are furnishing this letter and the enclosed documents in order to maintain the Company's exemption and to comply with the requirements of Rule 12g3-2(b)(1)(iii) of the Exchange Act.

Pursuant to Rule 12g3-2(b)(4), the information contained in, and the documents enclosed with, this letter are not deemed "filed" with the SEC or otherwise subject to the liabilities of Section 18 of the Exchange Act. Furthermore, pursuant to Rule 12g3-2(b)(5), neither this letter nor the furnishing of such information and documents will constitute an admission for any purpose that the Company is subject to the Exchange Act.

The information set forth below is a summary of documentation which the Company has made public pursuant to Icelandic law or stock exchange rules, filed with a stock exchange (and which was made public by that exchange) and/or distributed (or made available for distribution) to its securities holders:

1. News release (May 3, 2007): Actavis Group hf. announces **Withdraw interest in Merck generics business.** (enclosed).
2. News release (May 7, 2007): Actavis Group hf. announces **Actavis Group hf. Quarterly report – Presentation of 1Q Results 9 May at 8:30.** (enclosed)
3. News release (May 8, 2007): Actavis Group hf. announces **Actavis Group hf. Quarterly report - 1Q Results 2007.** (enclosed)
4. News release (May 9, 2007): Actavis Group hf. announces **Actavis Group hf. Quarterly report – Presentation of 1Q Results 2007.** (enclosed)
5. News release (May 10, 2007): Actavis Group hf. announces **Actavis Group hf. Insiders' dealing – Date of transaction 9.5.2007.** (enclosed).

Handwritten signature and date: 5/18

Partners in alphabetical order


Arni Vilhjálmsson • Bjarnfreður Ólafsson • Einar Baldvin Axelsson • Erlendur Gíslason • Guðmundur J. Oddsson • Gunnar Sturluson, Managing Partner
Hákon Árnason • Helga Melkorka Óttarsdóttir • Hjördís Halldórsdóttir • Othar Örn Petersen • Ólafur Arinbjörn Sigurðsson
Pétur Guðmundarson • Ragnar Tómas Árnason
Jakob R. Möller of counsel

6. News release (May 10, 2007): Actavis Group hf. announces **Actavis Group hf. Company Announcement – Matching Halted, News Pending**.(enclosed)
7. News release (May 10, 2007): Actavis Group hf. announces **Actavis Group hf. Company Announcsement – Matching Novator makes a voluntary takeover offer for the entire class A common shares of Actavis Group**.(enclosed)
8. News release (May 10, 2007): Actavis Group hf. **announces Actavis Group hf. Company Announcement – Actavis receives non-binding takeover bid**. (enclosed)

If the SEC has any questions or requires any further information, please contact the undersigned at +354 5 400 300. Finally, I would greatly appreciate your acknowledging receipt of this letter and the enclosure by stamping the enclosed copy of this letter and returning it to me by fax. The number is +354 5 400 301.

Sincerely yours,

On behalf of Actavis Group


Ólafur Atínbjörn Sigurðsson, Partner
LOGOS legal services

Office of International Corporate Finance
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Mail Stop 3628
Washington, D.C. 20549

Reykjavik, May 10 2007
File no. 90-07-0158

Re: Actavis Group hf. (File No. 82-34959)
Submission Pursuant to Rule 12g3-2(b)(iii)

Ladies and Gentlemen:

By letter dated February 13, 2006, a submission to the Securities and Exchange Commission (the "SEC") was made on behalf of Actavis Group hf. (the "Company") in order to establish the Company's exemption from the registration requirements of Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 12g3-2(b) promulgated under the Exchange Act. We are furnishing this letter and the enclosed documents in order to maintain the Company's exemption and to comply with the requirements of Rule 12g3-2(b)(1)(iii) of the Exchange Act.

Pursuant to Rule 12g3-2(b)(4), the information contained in, and the documents enclosed with, this letter are not deemed "filed" with the SEC or otherwise subject to the liabilities of Section 18 of the Exchange Act. Furthermore, pursuant to Rule 12g3-2(b)(5), neither this letter nor the furnishing of such information and documents will constitute an admission for any purpose that the Company is subject to the Exchange Act.

The information set forth below is a summary of documentation which the Company has made public pursuant to Icelandic law or stock exchange rules, filed with a stock exchange (and which was made public by that exchange) and/or distributed (or made available for distribution) to its securities holders:

1. News release (May 3, 2007): Actavis Group hf. announces **Withdraw interest in Merck generics business.** (enclosed).
2. News release (May 7, 2007): Actavis Group hf. announces **Actavis Group hf. Quarterly report – Presentation of 1Q Results 9 May at 8:30.** (enclosed)
3. News release (May 8, 2007): Actavis Group hf. announces **Actavis Group hf. Quarterly report – 1Q Results 2007.** (enclosed)
4. News release (May 9, 2007): Actavis Group hf. announces **Actavis Group hf. Quarterly report – Presentation of 1Q Results 2007.** (enclosed)
5. News release (May 10, 2007): Actavis Group hf. announces **Actavis Group hf. Insiders' dealing – Date of transaction 9.5.2007.** (enclosed).


Partners in alphabetical order

Arni Vilhjálmsson • Bjarnfreður Ólafsson • Einar Baldvin Axelsson • Erlendur Gíslason • Guðmundur J. Oddsson • Gunnar Sturluson, Managing Partner
Hákon Árnason • Helga Melkorka Óttarsdóttir • Hjördís Halldórsdóttir • Othar Örn Petersen • Ólafur Arinbjörn Sigurðsson
Pétur Guðmundarson • Ragnar Tómas Árnason
Jakob R. Möller of counsel

6. News release (May 10, 2007): Actavis Group hf. announces **Actavis Group hf. Company Announcement – Matching Halted, News Pending.**(enclosed)
7. News release (May 10, 2007): Actavis Group hf. announces **Actavis Group hf. Company Announcement – Matching Novator makes a voluntary takeover offer for the entire class A common shares of Actavis Group.**(enclosed)
8. News release (May 10, 2007): Actavis Group hf. **announces Actavis Group hf. Company Announcement – Actavis receives non-binding takeover bid.** (enclosed)

If the SEC has any questions or requires any further information, please contact the undersigned at +354 5 400 300. Finally, I would greatly appreciate your acknowledging receipt of this letter and the enclosure by stamping the enclosed copy of this letter and returning it to me by fax. The number is +354 5 400 301.

Sincerely yours,
On behalf of Actavis Group.



Ólafur Ágínbjörn Sigurðsson, Partner
LOGOS legal services

Actavis Group hf. Company Announcement - Withdraw interest in Merck generics business

Reykjavik, Iceland, 3 May 2007 ? Actavis Group (OMX: ACT) announces that it has withdrawn its interest to acquire the generics division of Merck KGaA. Actavis has performed extensive due diligence on the division and identified significant potential synergies with Actavis operations. However, the Board of Actavis considers that at the price levels that Actavis understands are being offered for the division by other bidders, the transaction would not produce value for Actavis' shareholders and therefore to proceed to the next stage of the bidding process would not be in their best interests.

Actavis is very well supported by its relationship banks and has the financial capability to undertake major acquisition opportunities such as the generics division of Merck KGaA as well as other targets. Actavis will continue to evaluate other acquisition opportunities to ensure the business remains at the forefront of a rapidly consolidating industry and to complement the strong growth profile of its own operations.

For further information:
Actavis Group

Halldor Kristmannsson, VP Corporate Communications
(+354) 535-2300 / 840-3425
hkristmannsson@actavis.com

About Actavis Group

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in more than 30 countries, with over 11,000 employees. The Company's market cap is approximately EUR3.0bn (US\$3.8 billion) and it's listed on the OMX Exchange in Iceland. For further information, visit www.actavis.com

RECEIVED
2007 MAY 17 A 9:13
BIC OF INTERMEDIATE
CORPORATE FINANCE

Actavis Group hf. Quarterly report - Presentation of 1Q Results 9 May at 8:30

Reykjavik, Iceland, 7 May 2007 — Actavis Group (OMX: ACT), the international generic pharmaceuticals company, announces that it will host a conference call on Wednesday 9 May at 13.30 GMT/ 14.30 BST/ 09.30 ET for European and US investors to discuss earnings.

Actavis' earnings press release will be made available after the close of the OMX Stock Exchange in Iceland on Tuesday 8 May 2007, around 17.00 GMT

Live conference call for analysts and investors:
Robert Wessman, President and Chief Executive Officer and Mark Keatley CFO, will host the live Conference Call for analysts and investors, the details of which are as follows:

Conference Call for European and US Investors

Time of call: 13.30 GMT/ 14.30 BST/ 09.30 ET
UK Dial in: + 44 (0)20 7806 1960
US / Canada dial in: + 1 718 354 1390
Password/Conf ID: Actavis Q1 Results

A presentation accompanying the conference call will be available on Actavis' website at www.actavis.com, in the investor relations section, one hour before the call.

Replay:

A replay of the presentation will be available on Actavis' website, and by telephone until 15 May.

Details are as follows:

UK: +44 (0)20 7806 1970 (Pin: 8854546#)
US / Canada: + 1 718 354 1112(Pin: 8854546#)

For more information, please contact Halldor Kristmannsson, Director of Corporate Communications, tel. +354 535 2325, +354 840 3425, email: hkristmannsson@actavis.com

About Actavis Group

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in over 30 countries, with 11,000 employees. The company's market capitalization is approximately EUR3bn (US\$3.8 billion) and is listed in the Iceland Stock Exchange. Actavis expects 2007 sales to total EUR1.6bn, with approximately one-third of these sales coming from the United States, the company's single largest market.

RECEIVED
2007 MAY 17 A 9 13
OFFICE OF THE SECRETARY
OF THE U.S. DEPARTMENT OF
COMMERCE

Actavis Group hf. Quarterly report - 1Q Results 2007

Actavis reports net profit of EUR27 million in 1Q

- Improved performance in Germany and UK drives underlying revenue growth of 8.3% -

RECEIVED
2007 MAY 17 A 9:13
OFFICE OF THE SECRETARY
CORPORATE AFFAIRS

Reykjavik, Iceland 8 May 2007 - Actavis Group (OMX: ACT), the international generic pharmaceuticals company, today announced results for the first quarter ending 31 March 2007.

1Q Highlights

- Reported revenue increased by 11.9% to EUR382.7 million (1Q 2006: EUR341.9 million)
- Underlying revenue increased by 8.3% (1Q 2006 pro forma: EUR353.5 million), reflecting strong performance in the UK, Germany and Russia.
- On a divisional basis:
 - Pro-forma sales in Central & Eastern Europe and Asia (CEEAA) increased to EUR157.2 million (1Q 2006 pro forma: EUR138.3 million). Underlying growth was 13.6%
 - Pro-forma sales in North America increased to EUR108.9 million (1Q 2006 pro-forma: EUR103.7 million), representing underlying growth of 5.0%
 - Sales in Western Europe, Middle East and Africa increased by 9.9% on a pro-forma basis to EUR79.7 million (1Q 2006 pro forma: EUR72.6 million)
 - Third Party sales declined 5.4% to EUR35.9 million (1Q 2006 pro forma EUR37.9 million)
 - EBITDA margin of 20.7% for the quarter, excluding distribution business. EBITDA margin is 23.1%
 - Net profit down by 15.3% to EUR27.0 million, underlying net profit (excluding purchase price amortisation), down 7.8% to EUR32.4 million
 - Underlying diluted earnings per share down 3.6% to EUR0.00660
 - 80 product and market launches (48 molecules), including 180 day exclusivity on Ranitidine oral solution in the US
 - Partnership agreements signed with large German insurance funds, to support further growth

Actavis President & CEO, Robert Wessman, commented:


"Actavis has a good start to the year, in line with our expectations. We continue to benefit from the diversity of our global business as well as the strength of our product pipeline, which has resulted in a significant product launch activity. It is particularly encouraging to see good improvement in Western Europe, supported by continued strong performance in the US and Russia.

Continued underlying growth combined with the impact of recent acquisitions means that we remain on track to meet our targets for the full year."

RECEIVED


2007 MAY 17 AM 9:27

OFFICE OF THE SECRETARY
U.S. DEPARTMENT OF JUSTICE




First quarter financial results

Analyst presentation 9 May 2007




Robert Weissman, President & CEO
Mark Keatley, CFO
Sigurdur O. Olafsson, Deputy CEO



Forward looking statement

Any statement contained in this presentation that refers to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors. Actavis does not undertake the obligation to update or alter these forward-looking statements beyond its duties as an issuer of listed securities on the Iceland Stock Exchange.

2



Today's speakers



Robert Weissman
President & CEO




Mark Keatley
Executive CFO



Sigurdur O. Olafsson
Deputy CEO





3



Agenda

1. First quarter highlights
2. Financial highlights
3. Sales performance
 - Own-label
 - North America
 - Central, Eastern Europe & Asia (CEE)
 - West Europe, Middle East and Africa (WEMEA)
 - Third-party sales
4. Q&A








Actavis Financial highlights 1Q 2007			
in EUR millions			
		Three months ended 31 March	
Euro millions		1Q 2007	1Q 2006
Total revenue.....		382.7	341.9
			11.9%
Total operating expenses.....		329.2	291.8
			(12.8%)
EBITDA.....		79.3	72.5
			9.4%
EBITDA %.....		20.7%	21.2%
			(0.5%)
Underlying net income.....		32.4	35.2
			(7.8%)
PPA adjustments.....		5.4	3.3
			(63.6%)
Net profit after PPA.....		27.0	31.9
			(15.3%)
Underlying diluted earnings per share.....		0.00660	0.00685
			(3.6%)
Reported diluted earnings per share.....		0.00491	0.00587
			(16.3%)


- Underlying net profit has been calculated prior to the amortisation of purchased intangibles
- Calculation of diluted EPS is in euros and takes full account of preferred shares and their dividend payments.

9



*Plus forma underlying growth, includes underlying growth from businesses acquired in 2006 to reflect the growth of the business as it is today, at constant exchange rates.





	1Q 2007 Actual
CAPEX	
Euro million	
Sites	
US.....	7.6
Malta.....	1.0
Iceland.....	3.6
Eastern Europe.....	11.0
India.....	1.2
Other.....	0.9
	25.3

17

Sources of cash flow	
Euro million	
Profit for the period.....	16,206.7
Depreciation and amortisation.....	27.0
Other adjustments.....	25.8
	(16.6)
Net cash provided by operating activities	35.4
Changes in operating assets and liabilities.....	
Receivables.....	(47.2)
Inventories.....	0.3
Payables.....	17.2
Net change in operating assets and liabilities	(2.7)
Net cash provided by operating activities	32.7


Average trade receivables 64 days
Inventory turns 3 x

18

Uses of cash flow	
Euro million	
Investment in property, plant and equipment (net)	(22.5)
Increase in intangibles	(20.2)
Net cash used in investing activities	(42.7)
Acquisitions.....	(40.3)
Net cash used in investing activities	(40.3)
Changes in net debt.....	87.6
Changes in capital stock.....	(6.0)
Net cash provided by financing activities	81.6
Net cash provided by financing activities	81.6
Effects of foreign exchange adjustments.....	(0.8)
Cash and cash equivalents at beginning of period.....	78.3
Cash and cash equivalents at end of period	65.7

19

Balance sheet	
Assets	
EUR million	
Trade Receivables	31/01/07 31/12/06
Inventories	301.3 724.2
Other Current Assets	777.6 277.9
Other Fixed Assets	178.7 169.8
Other Intangibles	497.9 467.3
Goodwill	515.0 504.2
Total Assets	2,735.0 2,579.4



actavis
Pharmaceuticals

2007 Guidance

- EUR1.6 billion in revenues
 - Underlying growth of 13%
 - Double digit growth in CEEA, Third-party and WEMEA
- EBITDA margin of 21-22%
- Over 500 product and market launches
- 40-45 ANDA filings in 2007 for the US market
- Revenue and EBITDA higher in second half than in first half
 - Active launch schedule and marketing campaigns in first half
 - Growing contribution from Abrika and Zio Zdravje

23

actavis
Pharmaceuticals


Financial targets 2007-2009

- Over EUR1.9 billion in revenues by end of 2009
- Improving COGS by 3% points from 2006 to 2009
- EBITDA margin growing from 20.8% in 2006 to 25% by end of 2009
- 20%+ annual growth in diluted EPS in 2007-2009
- Gaining top 5 position in key markets by end of 2009

24




25




Divisional overview

- Sales & marketing, Central & Eastern Europe and Africa (CEE&A)
- Own-label products either developed by Actavis or in-licensed from other companies
- Key markets include Turkey, Russia, Bulgaria & Romania
- Sales & marketing, Western Europe, Middle East and Africa (WEMEA)
- Own-label products either developed by Actavis or in-licensed from other companies
- Key markets include UK, Germany, Holland, the Nordic countries and Portugal
- Sales & marketing, Third-party global
- Sales of products developed by Actavis to third parties
- Key markets include Germany, France and the Netherlands
- North America division
- Presence established in the market following acquisitions of Amide Pharmaceuticals and the Human Generics Business of Alpiharma in 2005
- Sales of own-label products

26



27




Highest selling products in 1Q

EUR million

Product name	Originator (Company)	Therapeutic group	Division	Sales 1Q 2007
Gabapentin	Neurontin (Pfizer)	CNS	USA, WEMEA	9.9
Oxycodone	Numorphan (Biovail)	Cardiovascular	USA, CEEA, WEMEA	8.8
Ramipril	Roncodone (Mundipharma)	CNS	USA	8.4
Phenazone	Allace (Aventis)	Cardiovascular	TP, CEEA, WEMEA	8.3
Levetiracetam	Actavis	CNS	CEE	5.9
Trocarvastatin	Mevacor (Merck)	Cardiovascular	USA, CEEA, WEMEA	6.1
Carbidopa/Levodopa	Actavis	Cardiovascular	CEE	4.8
Cravate (Levodopa)	Sinemet (Merck)	CNS	USA, CEE	5.4
Citalopram	Tavanic (Sanofi-Aventis)	Anti-infective	CEE	4.4
	Ceftriaxone (Lundbeck)	CNS	TP, CEEA, WEMEA	5.4
Top 10 as a percentage of total revenue				17.6%

28

Product and market launches in 1Q



A total of 80 launches (48 molecules)

Thereof eight where Actavis was first to market

For new products and launches of existing products to new markets
Product is defined as molecule per pharmaceutical form, from own
development and includes marketing and co-development

29

North America sales



North America sales EUR108.9 million in 1Q

	1Q 2009	2Q 2009	3Q 2009	4Q 2009	1Q 2009	% QoQ
Sales	113.0	117.4	102.6	92.0	425.2	108.9
% of Group Revenues	33%	32%	32%	26%	31%	28%
Underlying Growth	14%	20%	(5%)	25%	13%	5%




Highlights:


- Underlying growth of 5% in the quarter
- Slightly ahead of management expectations
- Strong contribution from Ranitidine Syrup, with 180 day marketing exclusivity
- Strong sales of primary products
- Four new products launched

31


Central, Eastern Europe & Asia sales








37




Third-party sales


38



39



40



Investor & Media Relations:

Robert Weissman, President & CEO

Mark Keatley, CFO

Halldor Kristmannsson Vice President
Corporate Communications

Tel: +354 535 2300

Tel: +354 535 2300

Tel : +354 535 2300 /
+354 840 3425



Thank you



Actavis Group hf. Insiders' dealing - Date of transaction 9.5.2007

Directors Dealings

Name of insider:
Svend Andersson

Relations with the issuer:
Executive Vice President of sales in Western Europe, Middle East and Asia

Date of transaction:
9.5.2007

Buy or Sell:
Kaup / Buy

Type of instrument:
Hlutabréf / Equities

Number of shares:
74.000

Price:
78,2

Primary insider's holdings after the transaction:
3.574.000

Primary insider's option holdings after the transaction:
0

Related parties holdings after the transaction:
0

RECEIVED
2007 MAY 17 A 9:19
FICOF OF INVESTMENT
CORPORATE FINANCE

2007-05-10 12:19:37

Actavis Group hf. Company Announcement - Matching Halted, News Pending

Actavis Group hf. (International pharmaceutical company specializing in the development and sales of generic pharmaceuticals) symbol ACT, matching halted, news pending.

Actavis Group hf. Company Announcement - Novator makes a voluntary takeover offer for the entire class A common shares of Actavis Group

Novator, the investment firm led by Bjorgolfur Thor Bjorgolfsson, today announces that it will make a voluntary takeover offer for the entire class A common shares of Actavis Group hf. Parties related to Novator currently hold approximately 38.5% of the total class A common shares of Actavis Group hf. Mr. Bjorgolfsson is the Chairman of the Board of Directors of Actavis. Novator's intention is to acquire the entire class A common shares of the Company.

The offer will be made in Euros, by a new Company in the Novator Group. The offer price will be EUR 0,98 per share, which at the Icelandic Central Bank Fixing Exchange Rate for the Euro on May 9th equals ISK 85,23 per share. This represents a 9% premium to the Company's closing price at the OMX stock exchange on May 9th. This will be the highest price ever offered for the Company's shares, representing a premium of more than 21% to the six-month average closing price. Novator is of the opinion that this price fairly reflects the underlying value of the Company and is also fair when compared to other listed generic pharmaceutical companies and recent industry transactions.

The generic pharmaceutical industry has undergone rapid changes in recent years. Consolidation is continuously gaining pace, competition for leading positions in key markets is becoming ever more fierce, and pricing pressures continue to intensify. In such an environment, Novator views it as important for the successful future growth of the Company that it is taken private. In that way, it is no longer restrained by the obligations and requirements which are placed on listed companies, including that of disclosure. Therefore, Novator will seek delisting of Actavis from the OMX stock exchange as soon as practically possible.

Novator intends to fund a significant element of the transaction through debt funding. Therefore, it is clear that following the transaction, Actavis will be considerably leveraged on a consolidated basis. Novator will seek to adopt a more entrepreneurial and hence riskier approach to the Company's operations, to reduce the number of members of the Board of Directors and have significantly reduced public reporting responsibilities. Novator is of the opinion that the added risk, arising from increased leveraged and from a more aggressive style of corporate management, is not appropriate for general investors and that they should be presented with the opportunity to exit before such changes occur.

Novator hopes that the management and employees of Actavis will react favourably to this transaction and very much looks forward to a continued fruitful relationship.

The offer to all holders of class A common shares, along with the conditions thereof, will be formally made shortly, in accordance with provisions of the Icelandic Securities Act no. 33/2003 on voluntary takeover bids.

RECEIVED
2007 MAY 17 A 9:13
OFFICE OF INFORMATION
CORPORATE FINANCE

Actavis Group hf. Company Announcement - Actavis receives non-binding takeover bid

Reykjavik, Iceland, 10 May 2007 — Actavis Group (OMX: ACT) confirms that it has received an announcement from Novator, an investment firm led by the Chairman of Actavis, Bjorgolfur Thor Bjorgolfsson. Parties related to Novator, currently hold approximately 38.5% of total A class shares. Novator's intention is to acquire the entire class A common shares of the Company.

A new Company within the Novator Group intends to make a voluntary bid to all A class shareholders of Actavis in Euros. The offer price will be EUR 0.98 per share, which at the Icelandic Central Bank Fixing Exchange Rate for the Euro on 9 May, equals ISK 85.23 per share.

The Board of directors will review the offer as soon as feasible and make its recommendation to shareholders.

For further information:
Actavis Group

Halldor Kristmannsson, VP Corporate Communications
(+354) 535-2300 / 840-3425
hkristmannsson@actavis.com

About Actavis Group

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in more than 30 countries, with over 11,000 employees. The Company's market cap is approximately EUR3.0bn (US\$3.8 billion) and it's listed on the OMX Exchange in Iceland. For further information, visit www.actavis.com

END